An Innovative Approach to Studying and Treating Cancer: Targeting pH describes one of the few characteristics of cancer that is not shared by normal tissues: the reversal or inversion of the pH gradient when intracellular pH becomes alkaline and extracellular pH becomes acid. This is now recognized as one of the most selective and differential hallmarks of all cancer cells and tissues, being the opposite of the condition found in normal tissues and a potential target in order to achieve either a stable disease or even regression with no toxicity.
The book discusses topics such as lactic acid and its transport system in the pH paradigm, mechanisms to decrease extra cellular pH and increase intracellular pH, NHE-1 activity in cancer, carbonic anhydrases, vacuolar ATPase proton pump, and the sodium-bicarbonate cotransporter system. Additionally, it discusses complementary pharmacological interventions, cellular acidification and extracellular alkalinization as a new and integral approach to cancer treatment.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
PART 1: Metabolism and pH physiopathology of cancer1. Introduction2. Cancer metabolism3. The pH alterations in cancer: causes and consequences4. Lactic acid and its transport system5. The sodium hydrogen exchanger6. The voltage gated sodium channels7. Carbonic anhydrases8. Proton pumps9. The sodium/bicarbonate co-transporter10. Aquaporins11. Invadopodia and the migration/invasion process12. The Sp1 transcription factor
PART 1: Therapeutics13. Pharmacological interventions Part I14. Pharmacological interventions Part II15. Pharmacological interventions Part III16. Pharmacological interventions Part IV17. Therapeutics: the scheme18. Therapeutics: ancillary treatments19. Preventing metastasis20. Proton inhibitors in pets' cancer21. pH-related nanoparticles in cancer treatment22. Conclusions and future perspectives
Authors
Tomas Koltai Former Medical Director, Hospital del Centro Gallego de Buenos Aires, Argentina. Tomas Koltai is Board Certified Specialist in Medical Oncology (1985), PhD in Chemistry (1997) and Master's in Sciences in Molecular Oncology, University of Buenos Aires (2011). He has vast experience on cancer treatment at several positions: staff oncologist, Sanatorio Mater Dei, Argentina (1985-1990); Head of Oncology, Central Hospital of the Centro Gallego de Buenos Aires (1990-2000) and Medical Director, at the same institution (2000-2002); Head of the Department of Chemotherapy, National Social Services for Retirees, Argentina (2002-2014); Head of the Department of Oncology, Social Services of the National Food Workers Union, Argentina (2010-2014) and Medical Director at the same institution (2014-2016). He has authored several seminal publications on cancer and created the new "triple-edged cancer treatment�. Stephan J. Reshkin Associate Professor, Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, Italy. Stephan Reshkin, PhD, is molecular biologist and Associate Professor at the University of Bari (Italy). Dr. Reshkin has published 108 scientific papers, several book chapters and co-authored An Innovative Approach to Understanding and Treating Cancer: Targeting pH (Elsevier, 2020). His main research interests are cancer cell and pancreatic ductal adenocarcinoma. Salvador Harguindey Director, Institute for Clinical Biology and Metabolism, Vitoria, Spain. Specialty in Medical Endocrinology, Royal Infirmary Hospital, University of Edinburgh, Scotland (1974-1977) and Department of Endocrinology, Eugene Taldmage Memorial Hospital, USA (1977-1981). Specialty in Medical Oncology, Roswell Park Memorial Institute, USA (1981-1985). Consultant in Medical Oncologist, University Clinic, Spain ( 1985-2000).He co-founded and was Vice-president of the International Society for Proton Dynamics of Cancer (ISPDC) (2008). Co-editor and author on a special issue in Seminars in Cancer Biology (2017) entitled "The new pH-centric anticancer paradigm in Oncology and Medicine�.
Harguindey has published more than 140 scientific publications on a new and integral approach to the understanding of cancer and neurodegenerative diseases based upon hydrogen ion dynamics, from etiopathogenesis to treatment, that he originally and singlehandedly created.
